Literature DB >> 30378108

VEGF-C attenuates renal damage in salt-sensitive hypertension.

Shadia Beaini1, Youakim Saliba1, Joelle Hajal1, Viviane Smayra2, Jules-Joel Bakhos1, Najat Joubran3, Dania Chelala2, Nassim Fares1.   

Abstract

Salt-sensitive hypertension is a major risk factor for renal impairment leading to chronic kidney disease. High-salt diet leads to hypertonic skin interstitial volume retention enhancing the activation of the tonicity-responsive enhancer-binding protein (TonEBP) within macrophages leading to vascular endothelial growth factor C (VEGF-C) secretion and NOS3 modulation. This promotes skin lymphangiogenesis and blood pressure regulation. Whether VEGF-C administration enhances renal and skin lymphangiogenesis and attenuates renal damage in salt-sensitive hypertension remains to be elucidated. Hypertension was induced in BALB/c mice by a high-salt diet. VEGF-C was administered subcutaneously to high-salt-treated mice as well as control animals. Analyses of kidney injury, inflammation, fibrosis, and biochemical markers were performed in vivo. VEGF-C reduced plasma inflammatory markers in salt-treated mice. In addition, VEGF-C exhibited a renal anti-inflammatory effect with the induction of macrophage M2 phenotype, followed by reductions in interstitial fibrosis. Antioxidant enzymes within the kidney as well as urinary RNA/DNA damage markers were all revelatory of abolished oxidative stress under VEGF-C. Furthermore, VEGF-C decreased the urinary albumin/creatinine ratio and blood pressure as well as glomerular and tubular damages. These improvements were associated with enhanced TonEBP, NOS3, and lymphangiogenesis within the kidney and skin. Our data show that VEGF-C administration plays a major role in preserving renal histology and reducing blood pressure. VEGF-C might constitute an interesting potential therapeutic target for improving renal remodeling in salt-sensitive hypertension.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  NOS3; kidney; renal lymphangiogenesis; salt-sensitive hypertension; skin lymphangiogenesis; vascular endothelial growth factor C (VEGF-C)

Mesh:

Substances:

Year:  2018        PMID: 30378108     DOI: 10.1002/jcp.27648

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  10 in total

Review 1.  Inflammatory macrophages in the kidney contribute to salt-sensitive hypertension.

Authors:  Daniel J Fehrenbach; David L Mattson
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-27

2.  Heterozygous Mutation of Vegfr3 Reduces Renal Lymphatics without Renal Dysfunction.

Authors:  Hao Liu; Chitkale Hiremath; Quinten Patterson; Saumya Vora; Zhiguo Shang; Andrew R Jamieson; Reto Fiolka; Kevin M Dean; Michael T Dellinger; Denise K Marciano
Journal:  J Am Soc Nephrol       Date:  2021-09-22       Impact factor: 14.978

3.  Lymphangiogenic therapy prevents cardiac dysfunction by ameliorating inflammation and hypertension.

Authors:  LouJin Song; Xian Chen; Terri A Swanson; Brianna LaViolette; Jincheng Pang; Teresa Cunio; Michael W Nagle; Shoh Asano; Katherine Hales; Arun Shipstone; Hanna Sobon; Sabra D Al-Harthy; Youngwook Ahn; Steven Kreuser; Andrew Robertson; Casey Ritenour; Frank Voigt; Magalie Boucher; Furong Sun; William C Sessa; Rachel J Roth Flach
Journal:  Elife       Date:  2020-11-17       Impact factor: 8.140

Review 4.  Lymphatic Function and Dysfunction in the Context of Sex Differences.

Authors:  Claire E Trincot; Kathleen M Caron
Journal:  ACS Pharmacol Transl Sci       Date:  2019-09-09

Review 5.  The Molecular Mechanisms of Cardiotoxicity Induced by HER2, VEGF, and Tyrosine Kinase Inhibitors: an Updated Review.

Authors:  Qinchao Wu; Baochen Bai; Chao Tian; Daisong Li; Haichu Yu; Bingxue Song; Bing Li; Xianming Chu
Journal:  Cardiovasc Drugs Ther       Date:  2021-04-13       Impact factor: 3.727

Review 6.  The lymphatics in kidney health and disease.

Authors:  Michael D Donnan; Yael Kenig-Kozlovsky; Susan E Quaggin
Journal:  Nat Rev Nephrol       Date:  2021-06-22       Impact factor: 42.439

7.  Kidney-specific lymphangiogenesis increases sodium excretion and lowers blood pressure in mice.

Authors:  Dakshnapriya Balasubbramanian; Gaurav Baranwal; Mary-Catherine C Clark; Bethany L Goodlett; Brett M Mitchell; Joseph M Rutkowski
Journal:  J Hypertens       Date:  2020-05       Impact factor: 4.776

Review 8.  Body Fluid-Independent Effects of Dietary Salt Consumption in Chronic Kidney Disease.

Authors:  Jetta J Oppelaar; Liffert Vogt
Journal:  Nutrients       Date:  2019-11-15       Impact factor: 5.717

Review 9.  The role of lymphangiogenesis in cardiovascular diseases and heart transplantation.

Authors:  Rui-Cheng Ji
Journal:  Heart Fail Rev       Date:  2021-11-04       Impact factor: 4.654

10.  A Kidney-Targeted Nanoparticle to Augment Renal Lymphatic Density Decreases Blood Pressure in Hypertensive Mice.

Authors:  Bethany L Goodlett; Chang Sun Kang; Eunsoo Yoo; Shobana Navaneethabalakrishnan; Dakshnapriya Balasubbramanian; Sydney E Love; Braden M Sims; Daniela L Avilez; Winter Tate; Delilah R Chavez; Gaurav Baranwal; Mary B Nabity; Joseph M Rutkowski; Dongin Kim; Brett M Mitchell
Journal:  Pharmaceutics       Date:  2021-12-30       Impact factor: 6.525

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.